Core Viewpoint - The company has initiated a multi-dose escalation Phase Ib trial for its second-generation glucose kinase activator (GKA), HMS1005, in the United States, marking a significant step in its development for treating type 2 diabetes (T2D) [1] Group 1: Trial Details - The Phase Ib trial is a randomized, double-blind, placebo-controlled study aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of HMS1005 in T2D subjects [1] - The study will assess pharmacodynamic markers such as blood glucose, insulin, C-peptide, GLP-1, and glucagon in both fasting and fed states, along with continuous glucose monitoring (CGM) to explore the mechanism and effects of HMS1005 [1] Group 2: Product Characteristics - HMS1005 is a new molecular entity with improved physicochemical properties, designed as a sustained-release formulation to allow once-daily dosing, enhancing patient convenience and prolonging the drug's duration in the intestine [1] - The drug aims to improve the repair of GLP-1 secretion deficiencies in patients [1] Group 3: Future Plans - Upon successful completion of the Phase Ib trial, the company plans to seek partnerships for the global development of HMS1005 [1]
华领医药-B(02552.HK)第二代“GKA”美国Ib期试验首名患者成功给药